Status:
COMPLETED
Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)
Lead Sponsor:
Chinese University of Hong Kong
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The aim is to investigate whether Lamivudine 100mg daily is effective in the long term treatment of HBeAg negative chronic HBV infected patients with active liver disease in Asia
Detailed Description
Recent studies have proved lamivudine a very potent antiviral drug in suppressing viral replication and improving hepatic necro-inflammation with minimal adverse effects in HBeAg positive chronic hepa...
Eligibility Criteria
Inclusion
- Age=\>18 years
- HBsAg positive and HBeAg negative for at least 6 months prior to screening
- Serum HBV-DNA postiviet, HBeAg negative and HBeAb positive at the same timepoint on at least one occasion during the last 6 months
- ALT \>1.5 to 10 x upper limit of normal for at least two occasions within the previous 6 months and at screening, or ALT \> upper limit normal and with at least one biochemical flare-up (ALT \> 200IU/l) in the last 12 months.
- Informed writted consent
- Liver biopsy material/ slides taken within the previous 12 months, and at least 5 months after any previous antiviral treatment which show evidence of active liver disease (ie. evidence of necroinflammatory activity)
- Written informed consent
Exclusion
- Hepatocellular carcinoma
- ALT \> 10xULN at screening or history of acute exacerbation leading to transient decompensation
- Serum hepatitis C, hepatitis D or HIV
- Decompensated liver desease as indicated by any of the following: serum bilirubin \>3mg/dL, prothrombin time \>=2 seconds prolonged above upper limit of reference range, serum albumin \<28g/L, history of variceal haemorrhage, presence of intractable ascites at the screening assessment.
- Encepalopathy
- Planned for liver transplantation or previous liver transplantation
- Evidence of autoimmune hepatitis
- Amylase and/ or lipase \> 2 times upper limit of reference range
- Serum creatinine \>1.5 times upper limit of reference range
- Haemoglobin \< 11g/dL
- WBC count \<3x10\^9/L
- Platelets \<100x10\^9
- Serious concurrent medical illness other than hepatitis B
- Use of immunosuppressive therapy, immunomodylatory therapy or chronic antiviral thgerpay with other agents within the previous 6 months or during the study
- Previous treatment with lamivudine or famciclovir within the last 6 months
- History of hypersensitivity to nucleoside analogues
- Women of childbearing potential not practising adequate contraception
- Pregnancy or lactation
- Receipt of any investigational drug within 30 days of the first dose of study drug
- Child-Pugh class B or C cirrhosis
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
End Date :
January 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00338780
Start Date
November 1 2000
End Date
January 1 2005
Last Update
October 30 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital
Hong Kong SAR, China